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Background: Inhaled drugs are the mainstay of treatment for lung diseases such as asthma and chronic
obstructive pulmonary disease. However, failure to use inhalation devices correctly can lead to a poorly
controlled status. A vast number of inhalation devices exist and each device has speciﬁc requirements to
achieve optimum inhalation of the drug. Currently, there is no overview of inhalation requirements
considering all devices. This article presents a review of the literature on different inhalation device
requirements and incorporates the data into a new inhalation ﬂow algorithm.
Methods: Data from literature on commercially available inhalation devices were evaluated and pa-
rameters, such as inhalation ﬂow rate, ﬂow acceleration, inhalation volume, and inspiration time
assessed for the required inhalation maneuver speciﬁc to the device. All agreed upon data points were
used to develop an inhalation ﬂow algorithm.
Results: The literature analysis revealed availability of robust data for the required inhalation ﬂow
characteristics for most devices and thus for the development of an algorithm. For those devices for
which these parameters are not published, the minimum required ﬂow criteria were deﬁned based on
published data regarding individual aspects of aerosol quality.
Conclusions: This review provides an overview of inhalation devices available on the market regarding
requirements for an acceptable inhalation maneuver and shows which goals should be achieved in terms
of inhalation ﬂows. The presented algorithm can be used to develop a new computer based measure-
ment system which could help to test and train patients' individual inhalation maneuvers with their
inhalation devices.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Inhalation is the preferred route of drug administration for pa-
tients with lung diseases such as asthma and chronic obstructive
pulmonary disease (COPD). The development and introduction of
the pressurized metered dose inhaler (pMDI) in 1956 provided the
ﬁrst handy, reliable inhalation device [1,2]. In the following period,
the device became a worldwide success [2]. The quality of pMDIs
has continually improved over time, particularly since the ban on
chloroﬂuorocarbons (CFCs) [2]. With the required changeover to
alternative propellants, several products were fundamentally
modiﬁed, which also led to changes in aerosol quality that were
relevant for practice [1e6]. Key achievements since the switch from
CFC to HFA (hydroﬂuoroalkane) are devices with slower exit ve-
locities and warmer plumes [2,3,6]. A reduction in speed, combined
with smaller particles for some products, led to signiﬁcantly
improved lung deposition of the active drug particles [1,2,4e6].
Next to pMDIs, dry powder inhalers (DPI) play a signiﬁcant role in
the treatment of diseases such as asthma and COPD. In 1987, the
ﬁrst multidose DPI device with budesonide, an inhaled gluco-
corticosteroid (ICS), was used [7]. Today, in addition to pMDIs, there
are a number of devices availablewithmedications in powder form.
The quality of inhalation devices is generally high and active
drug delivery is reliable if the devices are used properly. The key
factors for successful inhalation, however, involve the right particle
size and a proper respiratory maneuver on the part of the patient
[6,8]. Each inhalation device requires a speciﬁc preparation for
reliable drug delivery. One of the most common sources of errors in
the application of pMDIs is the lack of coordination between
inhalation and the actuation of the inhaler [6]. With DPIs, inspira-
tory ﬂow rates that are either to low or lack the necessary initial
acceleration compromise treatment success [6].While the handling
of the inhaler, such as preparation (e.g. removing the protective cap
and preparing the dose), positioning of the device (e.g. keeping it
vertical) and follow-up (such as replacing the protective cap and
storing it in a dry place) can be monitored by a therapist observing
the inhalation process, there is currently no validated and easily
available method in place for monitoring the quality of the com-
plete inhalation maneuver with different devices.
In an editorial entitled “Dry Powder Inhalers and the Risk of
Error”, Terzano formulated the following questions and re-
quirements regarding the necessary inhalation energy in the
application of breath-actuated DPIs: “The issue of ﬂow indepen-
dence makes it imperative to determine two parameters for all
breath-actuated DPIs: Below which ﬂow rate does the DPI perfor-
mance fall dramatically? Above which ﬂow rate does the DPI per-
formance become fairly stable?” [9] Similarly, Laube et al. pointed
out in their task force report that “no manufacturer has stated the
minimum ﬂow for their DPI, although it is clear that this infor-
mation is needed.” [6].
An overview of such ﬂow limits for all inhalation devices on the
market is still lacking. However, these data are necessary to assessthe quality of an individual inhalation maneuver. For the develop-
ment of a new computer-assisted measurement system that can be
used to measure and assess multiple aspects of the inhalation
maneuver with original devices including inspiratory ﬂow rate,
inhalation time, acceleration rate, and inhalation volume, it was
necessary to determine a measuring algorithm based on known
and published data regarding ﬂow value limits of inhaler re-
quirements and inhalation quality.2. Materials and methods
A literature search was conducted for publications released
between 1980 and 2015 with the aim of determining all de-
pendencies of inhaler performance on inhalation ﬂow rate and
inhalation maneuvers. The year 1980 was chosen to ensure that we
included and discussed all relevant data on optimum inhalation
ﬂow rates for modern DPIs which were ﬁrst launched in 1987. No
years prior to 1980 were reviewed, as they could not include data
on HFA-MDIs. Search terms included “inspiratory ﬂow”, “inhalation
maneuver”, “inhalation technique”, “inhalation volume”, “ﬂow ac-
celeration”, “drug delivery”, “inhalation device”, and speciﬁc
product names. Furthermore, parameters that are important for
good inhalation results with commercially available inhalation
devices, including pMDIs, DPIs, and breath-actuated inhalers (BAIs)
were searched for including the following: minimum required
inspiratory ﬂow rates (bottom limit of the ﬂow rate), optimum
inspiratory ﬂow rates, maximum inspiratory ﬂow rates (upper limit
of the inspiratory ﬂow rates), ﬂow acceleration, inspiration time, as
well as inhaled volume after release or achievement of the mini-
mum required inspiratory ﬂow. The results of the search were
complemented by literature cited in review articles. Publications
were considered for review if they provided clear product speciﬁc
information regarding effects of various ﬂow parameters (e. g. ﬂow
rate) on clinical outcome and/or on aerosol quality criteria such as
output, mass median aerodynamic diameter (MMAD), ﬁne particle
dose (FPD) and ﬁne particle fraction (FPF). If publications did not
meet these criteria they were excluded, no other exclusion criteria
were used. Existing systematic reviews were included in this re-
view. Next to full published articles and reviews in English, German
text books and publications as well as editorials, instructions for
use, poster abstracts, summary of product characteristics, the
United States Pharmacopoeia, assessments of the European Medi-
cines Agency (EMA) as well as othermaterials that were considered
to be important to the topic were included in this review.
Data for inhalation ﬂow rates and  if deemed necessaryeother
inhalation parameters are presented and discussed for individual
inhalers. All agreed upon data points were then used to develop a
new algorithm which could be used to measure and interpret
quality of the inhalation maneuver with different inhalation
devices.
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The review of the literature revealed obstacles in making clear
distinctions between optimum (sufﬁcient) inhalation ﬂow rates
and still acceptable (borderline) ﬂow rates for each device. Mini-
mum required inspiratory ﬂow rates to deposit the medication
dose in the airways are described for some inhalers. In some cases,
however, these are too low for optimal therapeutic effects. Data
regarding ﬂow value limits of inhaler requirements and inhalation
quality are described in detail for individual inhalers.
3.1. Pressurized metered dose inhalers (pMDIs)
As stated in most literature, patients should inhale slowly when
using a pMDI [6,10e19]. However, for physical reasons, there must
be a minimum inspiratory ﬂow rate for pMDIs below which the
ﬂow rate should not drop. So far, there have been very few studies
or publications addressing this topic. Von Hollen et al. showed that
for inspiratory ﬂow rates of 15 L/min, the oropharyngeal deposition
values for all 3 of the pMDIs investigated in this study (QVAR® HFA,
ProAir® HFA, Atrovent® HFA) were higher than for ﬂow rates of
30 L/min [10]. Therefore, an optimum inspiratory ﬂow rate through
a pMDI should at least be greater than 15 L/min while the lower
limit for an acceptable ﬂow rate is 10 L/min.
With respect to the precise optimum inhalation ﬂow rate for
pMDIs, no conclusive information on “modern” HFA aerosols is
reported in the literature. For inhalation of terbutaline with a CFC
metered dose inhaler, Newman et al. determined in 1980 an opti-
mum inhalation ﬂow rate of 25 L/min [16]. While Laube et al. rec-
ommended a ﬂow rate of approximately 30 L/min as ideal [6], the
source on which they base their recommendation does not provide
any exact ﬂow rate data and only states that the inhalation ﬂow rate
for pMDIs should be as low as possible [17]. Elliott et al. also stated
that pMDIs typically require an inspiratory ﬂow rate of 30 L/min
[18]. However, this advice may be considered as ‘historical’, since
the development of HFA aerosols quality is not taken into account.
Given the availability of new evidence, it may be time to revise the
limits of the optimum ﬂow rate of pMDIs. The Easi-Breathe®, a
breath actuated inhaler (BAI) is already triggered at 20 L/min [6]
and this trigger limit for drug delivery is also accepted by regula-
tory authorities. Based on this information, we deﬁned a ﬂow rate
of 20 L/min as the lower limit for an optimum inhalation ﬂow for
the measurement algorithm for all pMDIs.
Although pMDIs are generally considered to be relatively similar
in terms of optimal technique, there are differences in terms of
consistency of FPF at different ﬂow rates between various devices.
Based on the data of Johal et al., in which one pMDI delivered
constant FPF at 30 and 60 L/min and another one released a higher
FPF at 60 L/min than at 30 L/min, it could be assumed that there are
differences among various pMDIs in terms of minimum ﬂow rates
[14,15]. Since most devices on the market are generic and product
speciﬁc data are available for only a few drugs, it is currently not
possible to determine whether for some systems a higher mini-
mum required inspiratory ﬂow rate should be recommended.
However, in order to achieve optimum therapy results somewhat
higher ﬂow rate values should therefore be targeted.
Prior to the changeover from CFCs to HFAs the recommended
maximum inspiratory ﬂow rate for inhalation with pMDIs was
around 60 L/min [11]. As with all device types, there is increased
risk of impaction at the back of the throat with fast inhalation ﬂow
rates [20]. However, Farr et al. have shown that pMDIs may not be
as dependent on keeping below 60 L/min as is often thought [12].
Lung deposition results for a salbutamol CFC-pMDI (Ventolin®)
from a microprocessor-controlled device (SmartMist) at different
release times and slow, moderate and rapid inspiratory ﬂow rates(30, 90 and 270 L/min) showed better lung deposition results with
inspiratory ﬂow rates of 90 L/min thanwith 30 L/min [12]. Changes
in aerosol characteristics due to the change in propellants compli-
cate the interpretation of studies performed in the CFC era. Many
older study results on deposition characteristics of CFC pMDIs and
the resulting recommendations for use may no longer be helpful
today. More recent data obtained with HFA pMDIs allow the
conclusion that the upper limit for inspiratory ﬂow rates is
considerably higher than 90 L/min [13]. In their in vivo studies on
QVAR®, Leach et al. demonstrated that ﬂow rates up to around
137 L/min do not inﬂuence active drug deposition in the airways
[13]. Taking into account the characteristics of HFA, we deﬁned a
maximum ﬂow rate of 120 L/min as a useful upper limit for
measured inspiratory ﬂow rates for the measurement algorithm for
all pMDIs (including BAIs). Little has been reported in the literature
about the consequences of exceeding the upper limit. Therefore,
exceeding the limit does not necessarily constitute a critical
mistake. Nevertheless, training should be used to prevent the user
from exceeding the limit.
3.2. Spacers/valved holding chambers for use with pMDIs
Similar to pMDIs alone, little is known or published about the
minimum required inspiratory ﬂow rates for pMDIs with spacer
attachments.
Usmani et al. measured the effect of slow (mean (±SD):
30.8 ± 4.7 L/min) and fast (67.1 ± 16.7 L/min) inspiratory ﬂow rates
on lung deposition and clinical response (lung function) with
monodisperse particles. The aerosol generation and delivery sys-
tem in this study was comparable to that of an MDI with spacer
with no ﬂow dependence and no requirement for breath actuation
or coordination. Fast inhalation increased total lung deposition for
small (1.5 mm) particles but decreased total lung deposition of
larger particles (3 and 6 mm). Oropharyngeal deposition increased
for all particle sizes, but signiﬁcantly greater for the larger particles
[8]. Mitchell et al. measured the performance of different sized
valved holding chambers (VHC) as a function of ﬂow rate with an
Andersen eight-stage impactor. The ﬂow rate ranges they used
(28,3 L/min, 45 L/min and 60 L/min) were likely to be achieved by
users [21]. In a different study, von Hollen et al. measured the
impact of two different ﬂow rates on the aerosol quality of albuterol
with different spacer devices using a Next Generation Impactor
(NGI). The FPFs were similar with ﬂow rates of 15 and 30 L/min. The
MMAD was slightly smaller at 30 L/min compared with a ﬂow rate
of 15 L/min. The optimum ﬂow rate for the application of pMDI
with spacers is likely dependent on the combination of pMDI and
spacer in use [22]. In general, user instructions for spacers recom-
mend an inspiratory ﬂow rate around 30 L/min and below [22e24].
A ﬂow rate of less than 15e20 L/min, the minimum ﬂow limit of
pMDIs in general, is possible with spacers but there is certainly a
minimum necessary ﬂow rate (>0), especially when VHC are used.
The valves have different resistances and a minimum effort is
necessary to open and close the valves. During tidal breathing in
young children the inspiratory ﬂow rate is about 8e16 L/min. This
could be too low for some VHC [25].
3.3. Breath actuated inhalers (BAIs)
With the Autohaler®, the spray is released when the device
reaches an inspiratory ﬂow rate of approximately 30 L/min [6,19].
At lower ﬂow rates, the user cannot trip the lock-outmechanism for
the dose delivery, which means that no drug is released at ﬂow
rates below 30 L/min. To actuate the Easi-Breathe®, a ﬂow rate of
20 L/min is required [6,19]. These values were incorporated into the
algorithm.
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A large amount of data is available for the Turbohaler®. How-
ever, the literature refers to various products with different active
drugs and preparations. For this reason, despite the copious
amount of data, the exact evaluating of a speciﬁc Turbohaler®
product is difﬁcult.
In general, a strong ﬂow dependency is described for the Tur-
bohaler® [6,26e44]. For this device, lung deposition, mass output,
FPF, FPD and MMAD are considered to be dependent on the
inspiratory ﬂow rates used (Table 1). The ﬂow rate range of
approximately 30 L/min to 60 L/min is considered a gray area for
the Turbohaler®. On the one hand, at a ﬂow rate of 30 L/min mass
output and an effect are measured; on the other hand, the results
regarding aerosol quality are not optimum at ﬂow rates below 60 L/
min [14,26,32,34e36,39,40]. Abdelrahim et al. determined the dose
emission characterization of the Bricanyl® Turbohaler® (terbuta-
line) at 10, 20, 30, 40, 50 and 60 L/min [38]. While the MMAD only
showed a moderate dependence on inspiratory ﬂow rate when
above 30 L/min, the mass output and FPF varied depending on the
ﬂow rate used (Fig. 1aec). Although some data for the Turbohaler®
show that a low ﬂow rate can lead to clinical effects for the
administration of beta agonists (terbutaline), it is recommended
that the ﬂow rate should not be below a minimum of 30 L/min [6].
This is due to the fact that clinical drug efﬁcacy (measured in
conjunction with the inspiratory ﬂow rate) has so far only been
determined with beta agonists. However, these show a clinical ef-
fect even if only the large airways are reached. For a good anti-
inﬂammatory effect of ICS, though, a high FPF is of great impor-
tance. Therefore, the inhalation results are satisfactory only at rates
of approximately 60 L/min and higher [6,42,43].
With the introduction of the preparation Oxis® Turbohaler®, a
modiﬁed device (Flexhaler™) became commercially available
whose characteristics are slightly different from devices using
mono substances such as terbutaline (Bricanyl®, Aerodur®) or
budesonide (Pulmicort®). For example, the device resistance of the
Oxis® or Symbicort® Turbohaler® is around 10% lower than that of
former Turbohaler® generations [33]. For the “new” Turbohaler®
(used for formoterol monotherapy and budesonide/formoterol
combination) the aerosol output and quality also exhibit ﬂow
dependence in the ﬂow rate range between 30 and 60 L/min
[33,40,41]. The manufacturer AstraZeneca describes this ﬂow rate
dependence in the instructions for use of the Pulmicort®
Flexhaler™ (the Flexhaler™ is identical to the Oxis® and Symbi-
cort® Turbohaler®) [41]. The instructions state that “in vitro testing
has shown that the dose delivery for the Flexhaler™ is dependent
on airﬂow through the device, as evidenced by a decrease in the
FPD at a ﬂow rate of 30 L/min to a value that is approximately
40e50% of that produced at 60 L/min. At a ﬂow rate of 40 L/min, the
FPD is around 70% compared to a FPD at 60 L/min.” [41] In a study
by de Boer et al. different DPIs were tested in vitro as a function of
the pressure drop (2, 4 and 6 kPa) across the inhaler and the effects
on FPF analyzed. Again, it was conﬁrmed that below the pressure
drop of 4 kPa, which corresponds to a ﬂow rate of 58.8 L/min, the
FPF (particle <5 mm) with the Symbicort® Turbohaler® falls signif-
icantly [44].
Based on the data in the literature, the following values were
incorporated into the algorithm: A ﬂow rate of <30 L/min for the
Turbohaler® was deﬁned as insufﬁcient while a ﬂow rate range
between 30 and < 60 L/min was deﬁned as acceptable but capable
of optimization. A ﬂow rate of 60 L/min allows for optimum
inhalation.
To deﬁne the acceleration of inspiratory ﬂow, the data of Everard
et al. and the values of the software algorithm of the Inhalation
Manager were used [27,45]. Using a Malvern Mastersizer (laserparticle sizer), Everard et al. found that “failure to attain a ﬂow rate
of 30 L/min before 150 mL of air had passed through a Turbohaler®
resulted in an aerosol volume median diameter increase from less
than 6.6 mm to greater than 45.3 mm” [45] For the treatment to be
successful, it is therefore important to inhale forcefully from the
start, especially when using the Turbohaler®. A ﬂow acceleration of
at least 0.7 L/s2 should be targeted [27]. Otherwise, the inhalation is
assessed as insufﬁcient.3.5. Diskus®
The Diskus® (Accuhaler®) is a medium resistance [6] multidose
powder inhaler with 60 individual doses in a rolled up blister strip.
For each inhalation, only one blister is opened and emptied. There
are sporadic indications that for the Diskus®, a ﬂow rate higher than
30 L/min can yield better inhalation results [26]. Kamin et al.
observed a very low mass output at ﬂow rate values < 60 L/min
(18 L/min and 30 L/min) compared to higher ﬂow rates (60 and
90 L/min) [26]. However, other in vitro and in vivo studies have
shown that at an inspiratory ﬂow rate of 30 L/min, constant
amounts of the active drug are delivered and that increasing the
ﬂow rate does not quantitatively or qualitatively improve the
released dose [6,46,47]. This value is also indicated as the minimum
required inspiratory ﬂow rate in international recommendations
[6]. The chosenminimum ﬂow rate for the Diskus® in the algorithm
was therefore maintained at 30 L/min.3.6. Novolizer®
The Novolizer® is a DPI with medium device resistance [6] so
that patients can achieve ﬂow rates of 90 L/min through the device
[20,48,49]. In the literature, various data are reported with respect
to the minimum required inspiratory ﬂow rates for the Novolizer®.
The data vary from 35 L/min [50], to 40 L/min [51], up to a range of
35e50 L/min [49,52e54]. Exceeding this limit does not limit the
delivery of the active drug. If the minimum ﬂow rate of 35 L/min to
50 L/min is reached, the Novolizer® emits an optical and acoustic
signal (feedback) to the patient [50]. As with many other DPIs, the
active drug is removed from the device evenwith a respiratory ﬂow
rate below this acoustic signal threshold value. The patient should
therefore be sure to inhale forcefully and quickly from the very
beginning.
As a ﬂow rate of 35 L/min is described in each literature refer-
ence, this value was incorporated into the algorithm as the mini-
mum required inspiratory ﬂow rate [49e54]. The optimum ﬂow
rate, however, starts at 50 L/min [49,52e54].3.7. Genuair®
The Genuair®, a DPI with medium resistance [55], looks nearly
identical to the Novolizer® device but has several modiﬁcations.
The minimum ﬂow rate that releases the trigger mechanism for the
acoustic and optical signal to the patient is, depending on the
publication, set at 45 L/min [56,57] or 40 L/min [58]. However, it has
also been described that the active drug is already delivered at a
ﬂow rate of 35 L/min, resulting in a clinically effective FPD within
the required speciﬁcations [57]. In another study it was shown that
a full dose of the drug is released at a ﬂow rate of25 L/min and at a
ﬂow rate of >35 L/min, a constant FPF is delivered. Despite these
results, Van der Palen recommended an optimum trigger ﬂow rate
for the Genuair® of 40 L/min [58]. Taking all data into account, we
deﬁned a value of 40 L/min as the minimum inspiratory ﬂow rate
for Genuair® and incorporated it into the algorithm.
Table 1
Overview of important inhaler characteristics and inhalation modes.
Device System Minimum required inspiratory ﬂow rate values (in L/min) Flow-resistance Important aspects
to consider
Recommended
inhalation mode [6]
Acceptable
inhalation
Good
inhalation
pMDI pMDI 10 20 Much lower in
comparison
to DPI [55]
Coordination
required [6]
Slow exhalation as
far as comfortable.
Slow and deep
inhalation (4e5 s)
through the mouth
until the lungs are
ﬁlled with air. At the
beginning of the
slow inhalation the
canister should be
pressed to actuate
the dose.
pMDI þ spacer pMDI þ add on
device
15 20 Low [55,88] Coordination required.
Coordination should
occur in periods
of seconds [6,89e92]
Slow exhalation as
far as comfortable.
Slow and deep
inhalation (4e5 s)
through the mouth
after actuation of
one dose into the
spacer. The inhalation
should start
immediately after
actuation
without delay.
Autohaler® Breath actuated
inhaler
30 30 Lower in
comparison
to DPI [55]
The threshold value
is attained at 30 L/min [6]
Slow exhalation
as far as comfortable.
After starting to
inhale slowly through
the mouth the dose
is automatically
released. Patients
should maintain
the slow and deep
inhalation (4e5 s)
after dose actuation.
Easi-Breathe® Breath actuated
inhalers
20 20 Lower in
comparison
to DPI [55]
The threshold value is
attained at 20 L/min [6]
See recommended
inhalation mode of
Autohaler®, however,
the acoustic signal
of the actuation is
more quiet with
Easy-Breathe®.
Turbohaler® DPI-multidose 30 60 Medium-high [6]
Dose emission is
ﬂow-dependent [6]
Exhalation into
the room to
functional residual
capacity before
inhaling (no
exhalation into
the device). Forceful
inhalation through
the mouth from the
very beginning.
Diskus® DPI-blister 30 30 Medium [6]
Easyhaler® DPI-multidose 30 30 High [6]
Aerolizer® DPI-capsule 40 40 Low [6]
Handihaler® DPI-capsule 20 30 High [6]
Breezhaler® DPI-capsule 50 50 Low [55]
Ellipta® DPI-blister 30 30 Medium [55]
Spiromax® DPI-multidose 30 30 Medium-high [55]
Novolizer® DPI-multidose 35 50 Medium [6] After exceeding a
ﬂowrate threshold
of 35e50 L/min, an
acoustic (“click”) success
signal is emitted and the
inhaler is reset to prepare
the next dose. For this
reason, the threshold has
to be exceeded [52].
Genuair® DPI-multidose 40 40 Medium [55] After exceeding a ﬂowrate
threshold of 40 L/min, an
acoustic (“click”) signal is
emitted to reset the inhaler
to prepare the next dose.
For this reason, the threshold
has to be exceeded [58].
NEXThaler® DPI-multidose 35 35 Medium-high [55] Breath actuated threshold,
no drug delivery below
this threshold [71]
DPI ¼ dry powder inhaler; pMDI ¼ pressurized metered dose inhaler.
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Fig. 1. 1) Bricanyl® Turbohaler® (terbutaline) ﬂow dependence on MMAD, mean values at different inspiratory ﬂow rates of 10 L/min to 60 L/min, b) Terbutaline (Bricanyl® Tur-
bohaler®) output, mean values in % of nominal dose at different inspiratory ﬂow rates of 10 L/min to 60 L/min, c) Terbutaline (Bricanyl® Turbohaler®) ﬁne particle fraction (FPF),
mean values in % of nominal dose at different inspiratory ﬂow rates (10 L/min to 60 L/min) (modiﬁed according to [38]).
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Different in vitro studies have shown that the minimum
required inspiratory ﬂow rate of the Easyhaler®, a DPI with high
resistance [6], is 30 L/min [59e62]. Vidgren et al. studied the ﬂow
rate dependence of the dose constancy of a salbutamol Easyhaler®
at ﬂow rates of 20, 28, 40 and 60 L/min. They showed that it was
possible to inhale a therapeutic dose even at a low inspiratory ﬂow
rate of 28 L/min, although the respirable fraction (deﬁned as par-
ticles <6 mm and respirable dose as the proportion of the delivered
particles) achieved with a ﬂow rate of 28 L/min (31.5%) was clearly
below the value reached at 60 L/min (45.2%) [59]. In comparison to
the Turbohaler®, the Easyhaler® is less dependent on the ﬂow rate
and delivers a higher FPF even at low ﬂow rates (30 L/min) [60].
Koskela et al. demonstrated that a low inspiratory ﬂow rate of 29 L/
min, the Easyhaler® (salbutamol) produces comparable improve-
ments in pulmonary function as a properly used pMDI with a
spacer [61]. Based on these studies the minimum required inspi-
ratory ﬂow rate for the Easyhaler® was deﬁned as 30 L/min and
incorporated into the algorithm.3.9. Aerolizer®
The Aerolizer® is a single-dose capsule DPI with a low resistance
[55] in which the active drug is inserted into the device in a gelatin
capsule. Prior to each use, a needle is used to pierce the capsule
which allows the active drug to be released. Compared with blister
or reservoir DPIs, for capsule-powder devices the dose is released
later and for this reason, inhalation quality depends on the volume
inhaled. In order to be sure to actually inhale the complete dose per
capsule, patients should repeat the inhalation procedure with the
same capsule [6].
Weuthen et al. used an Andersen Cascade Impactor (ACI) to
investigate the particle size distribution and MMAD generated by
the Foradil® P Aerolizer® at inspiratory ﬂow rates of 28.3, 40, 60,
and 80 L/min. Based on the results, a ﬂow rate range between 40
and 60 L/min was reported to be optimum [32]. Regarding the FPF
(in % of the delivered dose, particles <5.8 mm), the optimum ﬂow
rate of the Foradil P® Aerolizer® was reached at 80 L/min [32]. In
earlier studies, the Aerolizer® was tested in vivo in 16 children
between the ages of 8 and 15 with exercise-induced asthma. The
study compared prophylactic inhalation of 12 mg formoterol
inhaled at ﬂow rates of 60 and 120 L/min and the authors
concluded that the highest possible inspiratory ﬂow rate should be
reached in order to achieve the maximum effect [63]. In a more
recent study, however, the optimal inhaler performance was found
at 65 L/min. At this rate the pharyngeal deposition is low and the
release from the capsule and the FPF is high [64]. In contrast to
these results, Meyer et al. found that within a ﬂow rate range from30 to 130 L/min changes in lung deposition are less than 10% [65].
Due to the amount of published data in the literature, the
required minimum ﬂow rate through the Aerolizer®was deﬁned to
be 40 L/min for the algorithm. The optimum peak inspiratory ﬂow
rate is 65 L/min.
3.10. Handihaler®
The delivered dose of the Handihaler®, a DPI with high resis-
tance [20], was measured by Chodosh et al. in the ﬂow rate range of
20e60 L/min [66]. The results of studies using the ACI showed a
dose release at ﬂow rates as low as 20 L/min. It was further shown
that the FPD and FPF (deﬁned as the mass fraction of particles with
aerodynamic diameters up to 5.0 mm) were similar across the ﬂow
rate range from 28.3 to 60 L/min. However, if the ﬂow rate was
reduced from 28.3 to 20 L/min, the FPD decreased by 20% [66]. In a
more recent study, Lindert et al. have shown that the Handihaler®
performance was not affected by the ﬂow rate when ﬂow rates of
30 an 60 L/min were compared; only the standard deviations were
higher using a ﬂow rate of 30 L/min, suggesting that this value
represents a threshold [67].
Based on the results it can be concluded that the minimum
required inspiratory ﬂow rate is 20 L/min. At a ﬂow rate of 28.3 L/
min and higher, however, signiﬁcantly better drug delivery values
are achieved. Therefore, a ﬂow rate value of 20 L/min is acceptable
but a higher ﬂow rate on the order of approximately 30 L/min is
targeted. These values were incorporated into the algorithm.
3.11. Breezhaler®
The Breezhaler® is another DPI for which the individual doses
are in capsule form. The ﬂow resistance is comparatively low
[55,68e70]. In an in vitro study, Pavkov et al. reported on the ﬂow
rate dependency of the delivered dose. The dose delivery (indaca-
terol) was determined at ﬂow rates of 30e100 L/min. The aero-
dynamic particle distribution was determined with a NGI. At
inspiratory ﬂow rates of 50e100 L/min, approximately 80% of the
target dose was delivered and the ﬁne particle mass remained
consistent. At an inspiratory ﬂow rate of 100 L/min, a greater mean
dose could be delivered with a lower deviation [69]. Chapman et al.
described the results of an in vitro study inwhich the characteristics
of the delivered indacaterol dose from the Breezhaler® were
investigated. The study was performed using an NGI with an air
ﬂow rate of 100 L/min. Inhalation proﬁles of seven patients were
selected to be representative of a COPD population, including pa-
tients withmoderate and severe stages of COPD. The study revealed
that a ﬂow rate of 100 L/min generated a high FPF (deﬁned as
fraction of 150 mg label claim and particles <5 mm in diameter) of
26.8% and a comparably good intrathoracic deposition of 31%. The
Fig. 3. Schematic representation of fast (ee) and slow (—) inspiratory ﬂow accelera-
tion through a DPI and dose emission from multidose DPIs (reservoir or blister type,
except Nexthaler®) at fast (ee) and slow (—) inhalation … ¼ minimum required
inspiratory ﬂow rate. The slow acceleration reaches the threshold of the minimum
required inspiratory ﬂow rate too late, so that deagglomeration is insufﬁcient and the
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Based on the literature, the minimum required respiratory ﬂow
rate for the Breezhaler® is 50 L/min, with a maximum ﬂow rate of
approximately 100 L/min. The data of Pavkov et al. suggest an op-
timum peak ﬂow rate in the range of 90e100 L/min [69]. In this
ﬂow rate range the highest delivered dose and ﬁne particle fraction
are obtained.
3.12. NEXThaler®
The NEXThaler® is a DPI with medium/high resistance [55]
(containing beclometasone and formoterol) and with a breath-
actuated mechanism guaranteeing that the dose is released only
when a threshold inspiratory ﬂow rate of 35 L/min is achieved [71].
In vitro data have shown that the NEXThaler®DPI devicewas able to
consistently release a high FPF for inhalation ﬂows rates from 30 to
90 L/min [71].
For the algorithm, the minimum required inspiratory ﬂow rate
for the Nexthaler® was set at 35 L/min.
3.13. Ellipta®
Ellipta® is a device with medium resistance [55] containing the
active drugs ﬂuticasone furoate and vilanterol (ﬁxed combination).
According to Hamilton et al., the delivered dose from Ellipta® is
consistent over a ﬂow rate range of 43.5e130 L/min for both
investigated active drugs. Recently published in vitro data show
that the Ellipta® inhaler delivers doses close to the stated label
claim at ﬂow rates between 30 and 90 L/min [72].
Based on these data an exact lower limit for an acceptable
inspiratory ﬂow rate cannot be determined for the Ellipta®. Data
exist only within a measured ﬂow rate range and no exact data are
available below 30 L/min. However, good inhalation can be ach-
ieved with a value of 30 L/min and above, and these values were
therefore incorporated into the algorithm.
3.14. DuoResp® Spiromax®
DuoResp® Spiromax® is a novel multi-dose DPI with medium/
high resistance [55] containing the active drugs budesonide and
formoterol. Dose-delivery studies were performed using low-,
middle-, and high-strength DuoResp® Spiromax® and total emitted
doses were measured at various ﬂow rates (40e90 L/m. The resultsFig. 2. Literature data on the required inspiratory ﬂow rates for the use of the different inhala
improved, green ¼ sufﬁcient to optimum ﬂow rate, gray ¼ ﬂow rate that is high and shouhave recently been published and show that even though total
emitted doses tended to increase with ﬂow rate, the extent of
change was limited, so that all doses were within 15% of the
labelled quantity. The results of this study were essentially the
same for all three strengths of DuoResp® Spiromax®. The authors
concluded that a minimal inspiratory ﬂow rate of 30 L/min is
required for effective treatment but that a ﬂow rate of 60 L/min is
preferred [73]. For the algorithm, the minimum required inspira-
tory ﬂow rate was set at 30 L/min.3.15. Development of an algorithm
An overview of the required inspiratory ﬂow rates for the use of
different inhalation devices is shown in Fig. 2. The ﬂow rate re-
quirements have been deﬁned and described by means of a trafﬁc
light system. According to this diagram, ﬂow rate values that are too
low and therefore insufﬁcient for effective inhalation are displayed
in red. Borderline results such as minimum required inspiratory
ﬂow rates that do not yield optimum effectiveness yet are displayed
in yellow, and values with optimum mass output, lung deposition
and effectiveness outcomes are displayed in green. By looking at
data on normal inspiratory ﬂow rates (tidal breathing in seated
position: approximately 18 and 13 L/min for men and women,
respectively [74]), it can be seen that pMDIs can be used within the
range of tidal breathing. For DPIs additional effort is necessary to
overcome the device speciﬁc resistance to reach the required ﬂowtion devices. Red ¼ insufﬁcient ﬂow rate, yellow ¼ ﬂow rate that is borderline or can be
ld be reduced.
ﬁne particle dose is reduced (modiﬁed according to ﬁgures of [6,45,75,76]).
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peak inspiratory ﬂow rates of 300e400 L/min can be achieved
depending on age and height. Additional ﬂow resistances such as
DPI devices decrease these values signiﬁcantly.
Every breath-actuated DPI has a minimum threshold in terms of
ﬂow efﬁciency. If the inspiratory ﬂow rate is too low (or the ﬂow
acceleration below a threshold), deagglomeration is insufﬁcient
and a reduced dose is delivered (see Fig. 3) with a high MMAD and
low FPF [6,9,28].
The upper ﬂow limit for DPIs is generally physiologically limited
by higher resistances compared to MDIs. Moreover, when using
DPIs, patients should generally use a higher inspiratory ﬂow rate
from the very beginning in order to deagglomerate the powder [6].
As with MDIs, the in vitro outcomes of very high peak inspiratory
ﬂow rates with DPIs have rarely been reported in the literature. For
that reason, no clear upper ﬂow limit could be deﬁned for the al-
gorithm. Pharmacopoeias specify an upper limit of 100 L/min for
DPI testing [77] but higher ﬂow rates are possible with low resis-
tance DPIs [65,78]. For medium or high resistance DPIs, possible
peak ﬂow rates are restricted by physiological limits. Even though a
threshold must exist above which the improvement of aerosol
quality is compensated by an increased oropharyngeal impaction
[20], no exact value is described in the literature. For example,
Meyer et al. found that for the Aerolizer® device even for a large
ﬂow rate range from 30 to 130 L/min the changes in lung deposition
are less than 10% [65]. Therefore, it can be assumed that good lung
deposition results can be achieved with ﬂow rates of 120 L/min and
above not only for MDIs [13] but also DPIs. Because of this, the
maximum optimum ﬂow rate value for the algorithm was set at
120 L/min for MDIs as well as DPIs. Higher ﬂow rates could be
accepted but lower ﬂow rates (120 L/min) should be targeted.
For a good inhalation, further ﬂow criteria such as inhalation
time and volume are essential with all inhalation devices.
Regarding the device speciﬁc requirements for pMDIs and DPIs a
sufﬁcient length of inhalation time is needed as the inhalation
maneuver should last longer than the spray duration of pMDIs and
should be long enough for DPIs to deliver the powder dispersion.
The spray duration of pMDIs is between 150 and 360 ms [79]. For
the Aerolizer® it was shown that at a ﬂow rate of 60 L/min the
powder residence time was 6,5 ms [80]. For other DPI devices no
published data could be found. However, it is known that time of
dose-emission is not comparable between different devices [81].
The minimum inspiratory volume is derived from the anatomical
and physiological properties of adult patients [74]. A volume of
500 mL is prescribed for intubated and mechanically ventilated
adult patients as it is deﬁned as a value that guarantees drug de-
livery to the lower respiratory tract. An inspiratory volume of less
than 500 mL and an inhalation time of less than 1 s were therefore
deﬁned as deﬁciency indicators in the evaluation of a measured
inhalation maneuver [27]. With capsule DPIs, the user should
inhale at least a volume of 500 mL after reaching the minimum
required inspiratory ﬂow rate [27]. Inhaling with blister and mul-
tidose DPIs, the ﬂow acceleration is very important [6,27,45]. The
lower limit of ﬂow acceleration for use of DPIs (reservoir and blis-
ter) is 0,7 L/s2 [26,27]. Capsule Inhalers are an exception: the
importance of acceleration for quality of the aerosol is less signif-
icant due to slower drug delivery [6].
Overall, the threshold values determined from the literature are
the basis for the algorithm (Fig. 4) that can be used to reliably
measure and interpret individual inhalation maneuvers for each of
the considered inhalation devices.
For BAIs (Autohaler®, Easi-Breathe®) and the ﬂow triggered DPI
NEXThaler®, there is no necessity for monitoring the minimum
required inspiratory ﬂow rate as an acoustic signal is emitted when
the trigger threshold is reached. However, it is still a good idea tomonitor the inspiratory maneuver, since doing so allows other
criteria to be determined such as inspiratory volume, ﬂow accel-
eration and whether the inspiratory ﬂow rates are in the recom-
mended range.
Another issue that may affect the quality of the inhalation ma-
neuver is the duration of breath holding after inhalation as this
offers drug particles more time for to reach the airway wall by
sedimentation or Brownianmotion. This technique could be helpful
in reducing the exhalation of very ﬁne particles, but particle size,
aerosol speed and duration and depth of inhalation also have an
impact on drug deposition. It is questionable whether breath
holding time is critical during the inhalation of powder particles,
which must be inhaled with a fast and powerful airﬂow. Applying a
breath hold period after inhalation does not appear to be an
important constraint for DPI use by children [82]. There is no evi-
dence from studies demonstrating the assumption that breath
holding signiﬁcantly inﬂuences the clinical effects of inhaled
bronchodilators. This ﬁnding is supported by an analysis of the
ADMIT (Aerosol Drug Management Improvement Team) con-
sortium. The ADMIT members came to the result that…”no studies
have demonstrated improved bronchodilation or any long-term
therapeutic consequences as a result” [83]. However, since it is
possible that breath holding is beneﬁcial when using inhaler de-
vices, patients should be advised to hold their breath for at least 5 s
until we know more.
4. Discussion
This review of the literature revealed distinct differences be-
tween inhalation devices regarding the optimum inhalation ma-
neuver. Considering the multitude of different inhalation devices,
patients should be aware of the optimum inhalation maneuver
with their prescribed inhaler since incorrect inhaler usage is
recognized as a major factor in worsening of disease outcomes.
However, quite often inhalers are considered easy to use so that
patients do not receive adequate training even though it has been
estimated that up to 68% of patients do not use their pMDI or DPI
correctly [84]. At the same time, up to 67% of nurses, doctors and
respiratory therapists are also unable to adequately describe or
perform critical steps of inhaler use [84]. These data point to an
urgent need for better education as well as training and testing of
patients' inhalation maneuvers.
Currently available tools for testing inhalation quality usually
measure single inhalation parameters such as inspiratory ﬂow rates
but do not reproduce the patient's entire inhalation maneuver and/
or are not available for all product groups. One such measuring
device is the In-Check Dial®, a peak ﬂow meter that uses various
resistances imitating different inhalation devices to measure the
inspiratory peak ﬂow [85]. The In-Check Dial® can be used to test
whether patients are able to produce the required ﬂow rate for a
certain inhaler and whether the ﬂow rate is within an appropriate
range. Since only the maximum ﬂow rate can be determined, no
information is provided on the amount of time required to reach
this maximum ﬂow rate after onset of inhalation  information
that is very important for evaluating the inhalation process for DPIs.
“Whistles” are mouthpiece adapters or dummy devices that use a
whistle to provide information on whether the ﬂow rate during
inhalation was sufﬁcient or not. In-Check Flo-Tone® is one example
of this kind of adapter [86]. It was developed to facilitate the use of
pMDIs for patients. Similar to the In-Check Dial® the In-Check Flo-
Tone® does not provide further information on the inhalation
maneuver. Another measuring device is Vitalograph's Aerosol
Inhalation Monitor (AIM™). AIM™works with hygienic disposable
DPI and pMDI simulators. The measurement system tests the
inhalation maneuver by measuring and evaluating the actuation,
Fig. 4. Algorithm for the measurement and evaluation of patients' inhalation maneuver quality with different inhalation devices. The width and position of the horizontal white
font bars show which requirements apply concerning the various ﬂow parameters for the respective devices (vertical gray bars).
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the breath-hold time [87]. To illustrate the difference between good
and poor inhalation technique, a lung pictogram is used to sym-
bolize achievement of the goals. The AIM™ therefore offers a good
method for monitoring the use of a pMDI. However, the measure-
ment system does not offer reliable information for different DPIs.
Only one DPI simulator is available for testing all DPIs. The AIM™
DPI simulator has only moderate resistance and is therefore unable
to reproduce the range of DPIs available on the market. One
exception to the above is the “Inhalation Manager”, a computer-
assisted system that is able to reproduce and evaluate the quality
of the entire inhalation process using original devices [26,27].
When evaluating the quality of individual inhalations, the mea-
surement system draws on stored in vitro data and is able to esti-
mate the aerosol quality released from the tested device depending
on the inhalation maneuver for each inhalation. However, complex
in vitro measurements (using an ACI) are necessary to determine
ﬂow threshold values if new inhalation devices need to be incor-
porated into the system. With the algorithm presented in this pa-
per, a new computer based measurement system can be developed
which does not rely on extensive measurements but instead is
based on published data. It therefore allows rapid adaptation to
new inhalers and product innovations, provided that data exist and
are accurately described in the literature.
In conclusion, the gathered information in this review provides
a comprehensive overview of inhalation systems available on the
market regarding the requirements for an acceptable inhalation
maneuver and shows which goals should be achieved in terms of
inhalation ﬂows (for an overview of all inhaler characteristics see
Table 1). Although there are only a few possibilities in practice to
measure patients' inspiratory ﬂow rates, prescribers should ensure
that the patient can raise the required inspiratory ﬂow rate to
adequately operate the chosen inhalation device. The prescriber
also has to be aware that the requirements for ﬂow velocity,
inhalation time and volumes should be reached. The performance
of the patient (possibly depending on the severity of the disease) to
achieve the required thresholds should be considered when
selecting the inhaler. The presented algorithm can be used to
develop a new computer based measurement system which could
test all the above described ﬂow parameters. Such a measuring toolcould assist testing and training of patients' individual inhalation
maneuvers with their speciﬁc inhalation devices.
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